Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
European Journal of Cancer · 2023-02 · 180 · 9-20
DOI: 10.1016/j.ejca.2022.11.017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023-02. Verfasst von Andrea Casadei-Gardini und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Electronic address: casa…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Electronic address: casadeigardini@gmail.com.
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
- Department of Gastroenterology and Hepatology, Kindai University, Faculty of Medicine, Japan.
Zitieren
APA
Casadei-Gardini, A., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H. Y., Rimassa, L., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Kumada, T., Sakamoto, N., Iwamoto, H., Aoki, T., …, & Ohama, H. (2023). Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European Journal of Cancer, 180, 9-20. https://doi.org/10.1016/j.ejca.2022.11.017
Vancouver
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European Journal of Cancer. 2023;180:9-20. doi:10.1016/j.ejca.2022.11.017
BibTeX
@article{CasadeiGardini2023,
author = {Casadei-Gardini, Andrea and Rimini, Margherita and Tada, Toshifumi and Suda, Goki and Shimose, Shigeo and Kudo, Masatoshi and Cheon, Jaekyung and Finkelmeier, Fabian and Lim, Ho Yeong and Rimassa, Lorenza and Presa, José and Masi, Gianluca and Yoo, Changhoon and Lonardi, Sara and Tovoli, Francesco and Kumada, Takashi and Sakamoto, Naoya and Iwamoto, Hideki and Aoki, Tomoko and Chon, Hong Jae and Himmelsbach, Vera and Pressiani, Tiziana and Montes, Margarida and Vivaldi, Caterina and Soldà, Caterina and Piscaglia, Fabio and Hiraoka, Atsushi and Sho, Takuya and Niizeki, Takashi and Nishida, Naoshi and Steup, Christoph and Iavarone, Massimo and Di Costanzo, Giovanni and Marra, Fabio and Scartozzi, Mario and Tamburini, Emiliano and Cabibbo, Giuseppe and Foschi, Francesco Giuseppe and Silletta, Marianna and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Ochi, Hironori and Yasuda, Satoshi and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Shimada, Noritomo and Kawata, Kazuhito and Tada, Fujimasa and Ohama, Hideko},
title = {Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population},
journal = {European Journal of Cancer},
year = {2023},
volume = {180},
pages = {9--20},
doi = {10.1016/j.ejca.2022.11.017}
}
EUVIMED